BNTX:NASDAQ
BioNTech SE - ADR
95,25 $
arrow_downward
-0,50%(-0,48) 1D
96,00 $
arrow_upward
+0,79% (+0,75)bedtimeAfter hours
Closed: 7 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
95,17 $
High
97,46 $
Low
93,92 $
Mkt. cap
23,93 млрд
Avg. vol.
1,01 млн
Volume
828,04 м.
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,55 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
Open
95,17 $
High
97,46 $
Low
93,92 $
Mkt. cap
23,93 млрд
Avg. vol.
1,01 млн
Volume
828,04 м.
52-wk high
123,98 $
52-wk low
79,52 $
EPS
-7,55 $
Beta
1,22
Shares outstanding
251,20 млн
No. of employees
8 мың
News stories
From web sources and news partners
Stock Titan
·
1 сағат бұрын
Under a prearranged trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 24,000 shares.
GuruFocus
·
7 сағат бұрын
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
Investing.com Nigeria
·
18 сағат бұрын
Form 4 BioNTech SE For: 7 October By Investing.com
AD HOC NEWS
·
1 күн бұрын
BioNTech stock fell 1.96 percent despite a Buy consensus
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR